The FDA’s first premarket approval for a vapour product that has gone through the premarket tobacco product applications (PMTAs) process shows that it is not opposed to all vaping products, although it is also significant that it refused approval for all non-tobacco flavours (although menthol is still under review). Tobacco organisations praised the decision but said it needs to go further in future. Anti-tobacco and anti-vaping organisations’ responses ranged from guarded acceptance to continued rejection on general health or more specifically youth enticement grounds.
Get access to premium content that is normally only available for subscribers.
For the duration of a week, you can read our news analysis, identify market trends and understand upcoming changes in the industry, which will enable you to get ahead of your competitors.
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
By signing up you agree to our Terms and Conditions Please note trial access may take up to 24 hours to be granted as access must be qualified by a member of the ECigIntelligence team.